Tenax Therapeutics (TENX) Projected to Post Earnings on Tuesday

Tenax Therapeutics (NASDAQ:TENX) is anticipated to release its Q4 2025 results before the market opens on Tuesday, March 24th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:00 PM ET.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.88. On average, analysts expect Tenax Therapeutics to post $-1 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Tenax Therapeutics Trading Down 4.1%

TENX stock opened at $14.30 on Friday. The firm has a market cap of $89.23 million, a PE ratio of -10.75 and a beta of 1.41. The stock has a 50-day moving average price of $13.53 and a 200-day moving average price of $10.29. Tenax Therapeutics has a 1-year low of $4.63 and a 1-year high of $18.38.

Analysts Set New Price Targets

Several equities research analysts recently commented on TENX shares. Cantor Fitzgerald assumed coverage on Tenax Therapeutics in a research note on Tuesday, March 17th. They set an “overweight” rating and a $35.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Tenax Therapeutics in a research note on Monday, December 22nd. Lifesci Capital raised shares of Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday, March 12th. Guggenheim boosted their target price on shares of Tenax Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a research report on Monday, March 16th. Finally, William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a research note on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $29.67.

Institutional Trading of Tenax Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new position in Tenax Therapeutics during the 3rd quarter worth $92,000. Corient Private Wealth LLC bought a new position in shares of Tenax Therapeutics during the fourth quarter valued at about $151,000. Quadrature Capital Ltd bought a new position in shares of Tenax Therapeutics during the fourth quarter valued at about $252,000. Goldman Sachs Group Inc. purchased a new position in Tenax Therapeutics during the fourth quarter worth about $273,000. Finally, Citadel Advisors LLC boosted its position in Tenax Therapeutics by 318.1% in the third quarter. Citadel Advisors LLC now owns 43,253 shares of the specialty pharmaceutical company’s stock worth $329,000 after purchasing an additional 32,908 shares during the last quarter. 1.67% of the stock is owned by institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.